• Mashup Score: 0
    High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL - 10 month(s) ago

    In infants with acute lymphoblastic leukemia (ALL) associated with KMT2A gene rearrangements, measurement of MRD by multicolor flow cytometry (MFC) and by PCR for fusion gene transcripts (FGT) had high qualitative comparability, with an overall concordance rate of 87.4%, without regard to either the type of molecular rearrangement or the type of therapy patients received, a Russian research group…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Measurement of MRD by multicolor flow cytometry & PCR for fusion gene transcripts had high qualitative comparability in infants with #ALL associated with KMT2A gene rearrangements. Read more on Nucleus: https://t.co/6emwIIDTSt https://t.co/PNBbLwAXM1

  • Mashup Score: 1
    Teclistamab “Offers Substantial Clinical Benefit over Physician’s Choice of Therapy” in Triple-Class Exposed RRMM - 10 month(s) ago

    Among patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), those treated with the BCMA x CD3 bispecific antibody teclistamab in the single-arm MajesTEC-1 trial had significantly improved outcomes compared with a retrospective control arm consisting of patients who met the MajesTEC-1 key inclusion criteria and received physician’s choice (PC) of subsequent…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Among patients with triple-class exposed r/r MM, those treated with the BCMA x CD3 bispecific antibody teclistamab in the MajesTEC-1 trial had significantly improved outcomes. Read more about the trial results on Nucleus: https://t.co/Zu9XRnAEjh #MMsm https://t.co/IB4I4Am3Yh

  • Mashup Score: 1
    CAST regimen for acute GVHD prophylaxis after HSCT - 10 month(s) ago

    Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, Abatacept, and Short Course of Tacrolimus for GVHD Prevention Following Haploidentical Transplantation. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2023010545). A Phase Ib-II clinical trial found that a regimen of combined post-transplant cyclophosphamide (PTCy), abatacept, and short-course tacrolimus (CAST) reduced the rate of grades II-IV acute…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      A Phase Ib-II clinical trial found a regimen of combined post-transplant cyclophosphamide (PTCy), abatacept & short-course tacrolimus reduced the rate of grades II-IV acute #GVHD safely & effectively following haploidentical #HSCT. Read more on Nucleus: https://t.co/Fm1XnZj9X1 https://t.co/drMtla2fd2

  • Mashup Score: 1
    NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML - 11 month(s) ago

    Korean researchers have developed a next-generation sequencing (NGS) panel for measuring MRD in patients with acute myeloid leukemia (AML) that they say is highly sensitive, accurate, could be applied in clinical practice to about 78% of AML patients with somatic mutations identified at diagnosis, and could detect clones emerging during relapse early, thus improving prognoses. The study is…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      A next-generation sequencing panel for measuring MRD could be used clinically for about 78% of #AML patients with somatic mutations identified at diagnosis & has potential to detect clones emerging during relapse, thus improving progress. Read more: https://t.co/GtVqesyRfb https://t.co/bNnsiSA3ro

  • Mashup Score: 0
    Blinatumomab Added to Interfant-06 Chemotherapy “Safe and Efficacious” in Infants with Newly Diagnosed KMT2A-Rearranged ALL - 11 month(s) ago

    Blinatumomab added to the Interfant-06 chemotherapy regimen appeared safe and was highly efficacious in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia (ALL) compared with historical controls from the Interfant-06 trial. Two-year disease-free and overall survival were 81.6% and 93.3%, respectively, compared with 49.4% and 65.8%, respectively, in the Interfant-06 trial….

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      When added to Interfant-06 chemotherapy regimen, blinatumomab appeared safe and was highly efficacious in infants with newly diagnosed KMT2A-rearranged #ALL. Read more about the @NEJM published findings on Nucleus: https://t.co/89xWIVIT34 #Leusm https://t.co/SJVgFtcCbc

  • Mashup Score: 1
    Maintenance with ivosidenib post-HCT in IDH1-mutated AML - 11 month(s) ago

    Fathi AT, Kim HT, Soiffer RJ, et al. Multi-Center Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Clinical Cancer Research. 2023; (doi: 10.1158/1078-0432.CCR-23-0182). A Phase I trial testing the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib as maintenance therapy in patients with…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      A Phase I trial testing isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib as maintenance therapy in patients with IDH1-mutated #AML following #alloHCT found that it was safe and well-tolerated. Read more about the findings on Nucleus: https://t.co/q0mQpSStBU #Leusm https://t.co/R7O1kRG2n9

  • Mashup Score: 1
    Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up - 11 month(s) ago

    In this month’s Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow- up, recommendations for management of invasive candidiasis in transplant recipients, GD2-CART01 for relapsed or refractory high-risk neuroblastoma and more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      In this month’s Pharmacy SIG Literature Update: Updated results from TRANSCEND with longer follow-up, recommendations for management of invasive candidiasis in transplant recipients, GD2-CART01 for r/r high-risk neuroblastoma and more! https://t.co/HH5df1nFdb https://t.co/B7qBeIE0Yw

  • Mashup Score: 0
    Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology - 11 month(s) ago

    In a recent observational study, researchers from the University of Wisconsin have identified a CD4+/CD8+ double-positive T cell (DPT) population as a predictive marker of grade 2 or higher graft-versus-host disease (GVHD). Using a xenograft transplant model, the authors found that the CD4+/CD8+ DPT population is transcriptionally, metabolically, and phenotypically distinct from CD4+ or CD8+ T…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Researchers from @UWMedicine have identified a CD4+/CD8+ double-positive T cell population as a predictive marker of grade 2 or higher #GVHD, providing the first comprehensive insight into clinical significance of these cells in context of GVHD. https://t.co/GF88ErlG7r https://t.co/g1nvfj7HR6

  • Mashup Score: 0
    Controlling ambient oxygen levels reduces severity of GI GVHD in murine models - 11 month(s) ago

    Seike K, Kiledal A, Fujiwara H, et al. Ambient Oxygen Levels Regulate Intestinal Dysbiosis and GVHD Severity After Allogeneic Stem Cell Transplantation. Immunity. 2023; 56 (2): 353 (doi: 10.1016/j.immuni.2023.01.007). Researchers report that controlling ambient oxygen levels in the intestines may lessen the burden of graft-versus-host disease (GVHD) in allogeneic stem cell transplant…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      Controlling ambient oxygen levels in the intestines may lessen the burden of #GVHD in #alloSCT recipients. Read more on Nucleus: https://t.co/pc5Wc8pglV https://t.co/H0DzRjPHO0

  • Mashup Score: 0
    EAT It Up: In Preclinical Study, VEGF Blockade “Significantly Improves” Efficacy of Ex Vivo Armed T-Cells - 11 month(s) ago

    In preclinical models, the use of specific antibodies against vascular endothelial growth factor (VEGF) or VEGFR2 significantly improved the therapeutic efficacy of ex vivo armed T cells (EATs), increasing cytotoxic CD8+ tumor-infiltrating lymphoctytes and high endothelial venules (HEVs) in the tumor microenvironment. The study by Nai-Kong V. Cheung, MD, PhD, of Memorial Sloan Kettering Cancer…

    Source: ASTCT Nucleus
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASTCT
      ASTCT

      As published in @jitcancer, researchers from @MSKCancerCenter details the therapeutic potential of VEGF blockade using anti-VEGF or anti-VEGFR2 antibody in combination with tumor-specific EATS: https://t.co/QLgtd4Msg1 https://t.co/4vSQPTsdYa

Load More